Product
Mid-dose group
1 clinical trial
1 indication
Indication
Hepatocellular CarcinomaClinical trial
A Phase 1 Open-label, Single Arm Study Targeting Glypican-3 (GPC3) Chimeric Antigen Receptor Modified T Cells (CAR-T) for Treatment of Advanced Hepatocellular CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-08-31